Ranibizumab versus aflibercept for the treatment of vascularized pigment epithelium detachment due to age-related macular degeneration
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Ranibizumab versus aflibercept for the treatment of vascularized pigment epithelium detachment due to age-related macular degeneration
Authors
Keywords
Aflibercept, Age-related macular degeneration, Pigment epithelium detachment, Ranibizumab, Treatment
Journal
INTERNATIONAL OPHTHALMOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2018-02-05
DOI
10.1007/s10792-018-0833-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- One-Year Results of Aflibercept in Vascularized Pigment Epithelium Detachment due to Neovascular AMD: A Prospective Study
- (2016) Daniele Veritti et al. EUROPEAN JOURNAL OF OPHTHALMOLOGY
- The Incidence and Progression of Age-Related Macular Degeneration over 15 Years
- (2015) Nichole Joachim et al. OPHTHALMOLOGY
- Age-Related Macular Degeneration
- (2015) Sonia Mehta PRIMARY CARE
- RESPONSE OF PIGMENT EPITHELIAL DETACHMENTS TO INTRAVITREAL AFLIBERCEPT AMONG PATIENTS WITH TREATMENT-RESISTANT NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
- (2015) Geoffrey K. Broadhead et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- The Dry Form of Age-Related Macular Degeneration (AMD): The Current Concepts of Pathogenesis and Prospects for Treatment
- (2015) Hanna Zając-Pytrus et al. Advances in Clinical and Experimental Medicine
- Intravitreal ranibizumab for the treatment of fibrovascular pigment epithelial detachment in age-related macular degeneration
- (2014) Yiannis Iordanous et al. CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
- Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration
- (2013) Ursula Schmidt-Erfurth et al. OPHTHALMOLOGY
- VARIABLE RESPONSE OF VASCULARIZED PIGMENT EPITHELIAL DETACHMENTS TO RANIBIZUMAB BASED ON LESION SUBTYPES, INCLUDING POLYPOIDAL CHOROIDAL VASCULOPATHY
- (2013) Maiko Inoue et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- ALTERATIONS OF VASCULAR PIGMENT EPITHELIUM DETACHMENTS ASSOCIATED WITH AGE-RELATED MACULAR DEGENERATION DURING UPLOAD WITH INTRAVITREAL RANIBIZUMAB
- (2013) Armin Wolf et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- MULTIMODAL IMAGING OF PIGMENT EPITHELIAL DETACHMENT
- (2013) Sarah Mrejen et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- PIGMENT EPITHELIAL TEARS ASSOCIATED WITH ANTI-VEGF THERAPY
- (2013) Sibel Doguizi et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- Intravitreal Ranibizumab for Pigment Epithelium Detachment With Subfoveal Occult Choroidal Neovascularization: A Prospective 24-Month Case Series
- (2012) Maurizio Battaglia Parodi et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- Pathogenetische Konzepte zur Pigmentepithelabhebung bei exsudativer AMD
- (2010) S. Wasmuth OPHTHALMOLOGE
- INTRAVITREAL BEVACIZUMAB IN VASCULAR PIGMENT EPITHELIUM DETACHMENT AS A RESULT OF SUBFOVEAL OCCULT CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION
- (2010) Thomas Ach et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- OPTICAL COHERENCE TOMOGRAPHY–MEASURED PIGMENT EPITHELIAL DETACHMENT HEIGHT AS A PREDICTOR FOR RETINAL PIGMENT EPITHELIAL TEARS ASSOCIATED WITH INTRAVITREAL BEVACIZUMAB INJECTIONS
- (2010) CLEMENT K. CHAN et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- Effect of intravitreal ranibizumab in avascular pigment epithelial detachment
- (2009) M Ritter et al. EYE
- Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study
- (2008) David M. Brown et al. OPHTHALMOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started